NCT00328523View on ClinicalTrials.gov

TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,496

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
HypercholesterolaemiaHyperlipidaemia
Interventions
DRUG

MK-0653, ezetimibe

DRUG

Duration of Treatment: 3 months

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00328523 - TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060) | Biotech Hunter | Biotech Hunter